Design, synthesis, and biological evaluation of diaryl heterocyclic derivatives targeting tubulin polymerization with potent anticancer activities

Eur J Med Chem. 2023 Apr 5:252:115284. doi: 10.1016/j.ejmech.2023.115284. Epub 2023 Mar 16.

Abstract

A series of diaryl heterocyclic analogues were designed and synthesized as tubulin polymerization inhibitors. Among them, compound 6y showed the highest antiproliferative activity against HCT-116 colon cancer cell line with an IC50 values of 2.65 μM. Compound 6y also effectively inhibited tubulin polymerization in vitro (IC50 of 10.9 μM), and induced HCT-116 cell cycle arrest in G2/M phase. In addition, compound 6y exhibited high metabolic stability on human liver microsomes (T1/2 = 106.2 min). Finally, 6y was also effective in suppressing tumor growth in a HCT-116 mouse colon model without apparent toxicity. Collectively, these results suggest that 6y represents a new class of tubulin inhibitors deserving further investigation.

Keywords: Antitumor; CA-4; Colchicine binding site; Tubulin inhibitors.

MeSH terms

  • Animals
  • Antineoplastic Agents* / pharmacology
  • Cell Line, Tumor
  • Cell Proliferation
  • Drug Screening Assays, Antitumor
  • Humans
  • Mice
  • Molecular Structure
  • Polymerization
  • Structure-Activity Relationship
  • Tubulin Modulators / pharmacology
  • Tubulin* / metabolism

Substances

  • Tubulin
  • Tubulin Modulators
  • Antineoplastic Agents